Lantheus

We’re still reflecting on the incredible session last month with Kim Meninger, MBA, PCC, who joined our Women Leaders of #Lantheus Employee Resource Group (WLL-ERG) at the Field National Meeting to discuss “Building Your Influence Without Authority." Kim led an engaging discussion and shared actionable strategies for gaining support, building trusted relationships and maximizing communication skills.    Her expertise in leadership and workplace confidence resonated deeply with our group, and we’re excited to apply these insights in our daily work.     To learn more, check out her TEDx talk: https://bit.ly/4l49hom      #WomenLeaders #WomenInLeadership

This year’s #WorldHealthDay, an annual observance marking the founding of the World Health Organization, highlights the importance of access to quality healthcare and shaping better health outcomes for generations. Today also marks the start of the 30th anniversary of National Public Health Week recognizing the vital role public health plays in improving our well-being. Together, these observances remind us that we’re driven by our Purpose to #FindFightFollow disease.    At #Lantheus, we are dedicated to delivering better patient outcomes through our #radiopharmaceutical solutions and precision diagnostics that help healthcare providers detect and monitor diseases like #prostatecancer and #heartdisease. #NPHW

Welcome, Evergreen Theragnostics team, to #TeamLantheus! 🎉   We look forward to driving innovation as a combined organization and #LeadingRadiopharma. #Lantheus is committed to encouraging our team members’ growth, fostering collaboration and delivering operational excellence, and we are excited to join together in our shared Purpose to #FindFightFollow disease to deliver better patient outcomes.   #GoFurther

We are proud to support the innovative Precision Dosimetry Imaging Biomarker (PDIB) initiative from the Foundation for the National Institutes of Health Biomarkers Consortium. As a member, our cross-industry partners and #TeamLantheus will support the measurement and direction of radiopharmaceutical therapies, in hopes of revolutionizing cancer care and ultimately delivering better patient outcomes. As a #LeadingRadiopharma, we are committed to fostering breakthroughs in radiodiagnostics and radiotherapeutics and believe this project will enable physicians to better #FindFightFollow cancers with high unmet need. We look forward to all the incredible things we will achieve together! 

Congratulations to #Lantheus’ own Ann Marie Dawidczyk, head of Market Access, on being elected recently to lead the Medical Imaging & Technology Alliance (MITA) PET Group. Ann Marie will serve as Chair of the group in 2026 and was chosen for her #nuclearmedicine expertise. We’re glad to have her on #TeamLantheus and celebrate this win alongside her!    #FindFightFollow 

This #CelebrateDiversityMonth, we’re reflecting on and celebrating the differences that make our team members unique while acknowledging the common threads that unite us as #OneLantheus. Increased understanding of one another enables us to foster a culture of deeper respect and collaboration. #FindFightFollow

#NEWS: #Lantheus today announced that it has completed its previously announced acquisition of clinical-stage #radiopharmaceutical company Evergreen Theragnostics and its late-stage PET diagnostic agent for neuroendocrine tumors (NETs), which complements Lantheus’ therapeutic agent. The acquisition also advances Lantheus’ capabilities with the addition of Evergreen’s #radioligandtherapy manufacturing infrastructure, including a revenue-generating CDMO business. Read the full press release: https://bit.ly/4chwgZe #LNTH #LeadingRadiopharma #NETS

Each year on March 31st, #WorldTheranosticsDay honors Dr. Saul Hertz’s contributions to the molecular therapy field and the first therapeutic administration of radioiodine to a patient. Since this milestone, innovation in theranostics has come a long way; a recent renaissance in the space has many viewing radiopharmaceuticals as the next scientific frontier. At #Lantheus, we are focused on advancing our capabilities as the leading radiopharmaceutical-focused company through a diversified pipeline with the potential to help deliver better patient outcomes. Learn more about our pipeline: https://bit.ly/42HhGY9 #LeadingRadiopharma

On #NationalDoctorsDay, we celebrate all the physicians who work with #TeamLantheus to #FindFightFollow disease on behalf of patients through innovative radiopharmaceuticals. Thank you for your commitment to advancing science and patient health.      #GoFurther 

Next Wednesday, our Vice President of Isotope Strategy John Wiggins will be a panelist at Lumanity’s #CancerProgress 2025 meeting in New York City supporting the Damon Runyon Cancer Research Foundation. The panel “Commercializing Uphill: Realizing Challenging Propositions” will explore challenges and opportunities in bringing new modalities such as #radioligandtherapy to market.   Read the agenda: https://bit.ly/4gtwOM9   #oncology #TeamLantheus #FindFightFollow